The effect of oral anticoagulation on clotting during hemodialysis

Kidney International

Volumn 68, Issue 2, 2005, Pages 862-866

  Ziai, Farzad ^b   Benesch, Thomas ^b   Kodras, Katharina ^b   Neumann, Irmgard ^b   Dimopoulos Xicki, Lida ^b   Haas, Martin ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

Anticoagulation; Dalteparin; Hemodialysis; Phenprocoumon

Indexed keywords

ANTIBODY; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A ANTIBODY; D DIMER; DALTEPARIN; PHENPROCOUMON; UNCLASSIFIED DRUG; UREA; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ARTICLE; ARTIFICIAL KIDNEY; BLOOD CLOTTING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; FEMALE; HEMODIALYSIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; TREATMENT OUTCOME; UREA BLOOD LEVEL; CHRONIC KIDNEY FAILURE; DRUG COMBINATION; DRUG EFFECT; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; THROMBOSIS;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; BLOOD COAGULATION; CROSS-OVER STUDIES; DALTEPARIN; DRUG THERAPY, COMBINATION; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHENPROCOUMON; PROSPECTIVE STUDIES; RENAL DIALYSIS; THROMBOSIS;

EID: 26944468342     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00468.x     Document Type: Article

References (16)

1. VAZQUEZ E, SANCHEZ-PERALES C, GARCIA-CORTES MJ, et al: Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants? Int J Cardiol 87:135-139, 2003
2. KAWAMURA M, FIJIMOTO S, HISANAGA S, et al: Incidence, outcome, and risk factors of cerebrovascular events in patients undergoing maintenance hemodialysis. Am J Kidney Dis 31:991-996, 1998
3. VAZQUEZ E, SANCHEZ-PERALES C, BORREGO F, et al: Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J 140:886-890, 2000
4. STEIN PD, ALPERT JS, BUSSEY HI, et al: Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 119 (Suppl 1):S220-S227, 2001
5. VAIDYA S, GUGLIUZZA K, DALLER JA: Efficacy of anticoagulation therapy in end-stage renal disease patients with antiphospholipid antibody syndrome. Transplantation 77:1046-1049, 2004
6. ISHANI A, HERZOG CA, COLLINS AJ, FOLEY RN: Cardiac medications and their association with cardiovascular events in incident dialysis patients: cause or effect? Kidney Int 65:1017-1025, 2004
7. HULL R, RASKOB G, PINEO G, et al: A comparison of subcutaneous low-molecular weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 329:1370-1376, 1993
8. MEYER G, MARJANOVIC Z, VALCKE J, et al: Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. Arch Intern Med 162:1729-1735, 2002
9. LEE AY, LEVINE MN, BAKER RI, et al: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146-153, 2003
10. SAGEDAL S, HARTMANN A, SUNDSTRØM K, et al: A single dose of dalteparin effectively prevents clotting during haemodialysis. Nephrol Dial Transplant 14:1943-1947, 1999
11. FRANK RD, WEBER J, DRESBACH H, et al: Role of contact system activation in hemodialyzer-induced thrombogenicity. Kidney Int 60:1972-81, 2001
12. DAUGIRDAS JT: Second generation logarithmic estimates of single pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 4:1205-1213, 1993
13. JANSSEN MJ, DEEGENS JK, KAPINGA TH, et al: Citrate compared to low molecular weight heparin anticoagulation in chronic hemodialysis patients. Kidney Int 49:806-813, 1996
14. HAFNER G, SWARS H, EHRENTHAL W, et al: The control of anticoagulation in acute dialyses with sensitive laboratory parameters. Scand J Clin Lab Invest 52:289-296, 1992
15. SAGEDAL S, HARTMANN A, SUNDSTRØM K, et al: Anticoagulation intensity sufficient for hemodialysis does not prevent activation of coagulation and platelets. Nephrol Dial Transplant 16:987-993, 2001
16. POLKINGHORNE KR. MCMAHON LP. BECKER GJ: Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. Am J Kidney Dis 40:990-995, 2002